176 related articles for article (PubMed ID: 34248926)
21. Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.
Nie W; Qian J; Xu MD; Gu K; Qian FF; Lu J; Zhang XY; Wang HM; Yan B; Zhang B; Wang SY; Hu F; Li CH; Zhong H; Han BH
J Natl Compr Canc Netw; 2020 May; 18(5):582-589. PubMed ID: 32380463
[TBL] [Abstract][Full Text] [Related]
22. Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Chen YT; Seeruttun SR; Wu XY; Wang ZX
Front Oncol; 2019; 9():1432. PubMed ID: 31921683
[No Abstract] [Full Text] [Related]
23. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
von Pawel J; Bordoni R; Satouchi M; Fehrenbacher L; Cobo M; Han JY; Hida T; Moro-Sibilot D; Conkling P; Gandara DR; Rittmeyer A; Gandhi M; Yu W; Matheny C; Patel H; Sandler A; Ballinger M; Kowanetz M; Park K
Eur J Cancer; 2019 Jan; 107():124-132. PubMed ID: 30562710
[TBL] [Abstract][Full Text] [Related]
24. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
25. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
27. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
[TBL] [Abstract][Full Text] [Related]
28. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
29. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
Gandara DR; von Pawel J; Mazieres J; Sullivan R; Helland Å; Han JY; Ponce Aix S; Rittmeyer A; Barlesi F; Kubo T; Park K; Goldschmidt J; Gandhi M; Yun C; Yu W; Matheny C; He P; Sandler A; Ballinger M; Fehrenbacher L
J Thorac Oncol; 2018 Dec; 13(12):1906-1918. PubMed ID: 30217492
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
Liu W; Huo G; Chen P
Front Immunol; 2022; 13():909027. PubMed ID: 35799785
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
33. Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients.
Xiong A; Nie W; Zhou Y; Li C; Gu K; Zhang D; Chen S; Wen F; Zhong H; Han B; Zhang X
Front Immunol; 2021; 12():708558. PubMed ID: 34630387
[TBL] [Abstract][Full Text] [Related]
34. EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.
Li Z; Zhou Q; Wang Q; Wang H; Yue W
BMC Pulm Med; 2022 Sep; 22(1):356. PubMed ID: 36123678
[TBL] [Abstract][Full Text] [Related]
35. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
Provencio M; Ortega AL; Coves-Sarto J; Calvo V; Marsé-Fabregat R; Dómine M; Guirado M; Carcereny E; Fernández N; Álvarez R; Blanco R; León-Mateos L; Sánchez-Torres JM; Sullivan IG; Cobo M; Sánchez-Hernández A; Massuti B; Sierra-Rodero B; Mártinez-Toledo C; Serna-Blasco R; Romero A; Cruz-Bermúdez A
JAMA Oncol; 2023 Mar; 9(3):344-353. PubMed ID: 36520426
[TBL] [Abstract][Full Text] [Related]
36. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
37. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Bordoni R; Ciardiello F; von Pawel J; Cortinovis D; Karagiannis T; Ballinger M; Sandler A; Yu W; He P; Matheny C; Felizzi F; Rittmeyer A
Clin Lung Cancer; 2018 Sep; 19(5):441-449.e4. PubMed ID: 30017645
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
Wang C; Yu X; Wang W
Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
Blair HA
Target Oncol; 2018 Jun; 13(3):399-407. PubMed ID: 29785577
[TBL] [Abstract][Full Text] [Related]
40. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
